LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced its inclusion in the Russell Microcap Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The company stated that joining this widely followed benchmark is anticipated to increase its visibility among institutional investors and investment products that track Russell indexes, potentially driving greater interest and liquidity in its shares.
The milestone reflects progress under LIXTE's new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies, providing a gauge for the microcap segment of the equity market. Inclusion in such an index often leads to automatic buying by index funds and exchange-traded funds that replicate the index, which can enhance a company's shareholder base and market profile.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company primarily known for its cancer drug development. Its lead compound, LB-100, is a first-in-class clinical PP2A inhibitor that has shown tolerability in cancer patients with anti-cancer activity, potentially enhancing chemotherapies and immunotherapies. The company is also advancing proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. Additionally, through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is pioneering electronically controlled proton therapy systems for tumor treatment. The LiGHT System, its proprietary technology, aims to offer advantages over current proton therapy options. More information about Liora Technologies can be found at www.lioratechnologies.com.
The addition to the Russell Microcap Index marks a significant step for LIXTE as it seeks to broaden its investor base and support its strategic pivot. The company's shift toward AI energy infrastructure represents a diversification beyond its core oncology focus, potentially opening new revenue streams. For investors, inclusion in the index provides a signal of improved visibility and credibility, which could lead to increased trading activity and analyst coverage. The full press release is available at https://ibn.fm/r6l81. For more updates on LIXT, visit the company’s newsroom at https://ibn.fm/LIXT.
